Agenus (AGEN) Liabilities and Shareholders Equity (2010 - 2026)
Agenus' (AGEN) quarterly Liabilities and Shareholders Equity came in at $186.5 million in Q1 2026, down 6.87% year-on-year from $200.2 million in Q1 2025, and down 17.79% quarter-over-quarter from $226.8 million in Q4 2025.
Agenus (AGEN) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Agenus' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $186.5 million for Q1 2026.
- On a quarterly basis, Liabilities and Shareholders Equity fell 6.87% year-over-year to $186.5 million in Q1 2026; TTM through Mar 2026 was $832.4 million, a 13.06% decrease from a year earlier, with the FY2025 full-year figure at $226.8 million, changed 0.23% from the prior year.
- Liabilities and Shareholders Equity fell to $186.5 million in Q1 2026 per AGEN's latest filing, from $226.8 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $456.2 million in Q2 2022 and bottomed at $185.2 million in Q2 2025.
- The 5-year median for Liabilities and Shareholders Equity is $292.4 million (2024), against an average of $307.8 million.
- Across the five-year window, Liabilities and Shareholders Equity surged 137.22% in 2022 and slumped 37.86% in 2024, its largest moves.
- Year by year, Liabilities and Shareholders Equity stood at $413.6 million in 2022, then slipped by 24.09% to $313.9 million in 2023, then declined by 27.92% to $226.3 million in 2024, then climbed by 0.23% to $226.8 million in 2025, then slipped by 17.79% to $186.5 million in 2026.
- Per Business Quant, the three latest AGEN Liabilities and Shareholders Equity figures stand at $186.5 million (Q1 2026), $226.8 million (Q4 2025), and $233.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 78.88 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.55 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 39.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.25 Bn |
| 10 | Agenus | 184.05 Mn | 177.29 Mn | 33.74 Mn | 186.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 186.46 Mn |
| Dec 31, 2025 | 226.80 Mn |
| Sep 30, 2025 | 233.89 Mn |
| Jun 30, 2025 | 185.22 Mn |
| Mar 31, 2025 | 200.20 Mn |
| Dec 31, 2024 | 226.27 Mn |
| Sep 30, 2024 | 238.48 Mn |
| Jun 30, 2024 | 292.42 Mn |
| Mar 31, 2024 | 256.56 Mn |
| Dec 31, 2023 | 313.91 Mn |
| Sep 30, 2023 | 335.47 Mn |
| Jun 30, 2023 | 383.59 Mn |
| Mar 31, 2023 | 412.85 Mn |
| Dec 31, 2022 | 413.56 Mn |
| Sep 30, 2022 | 429.02 Mn |
| Jun 30, 2022 | 456.17 Mn |
| Mar 31, 2022 | 441.31 Mn |
| Dec 31, 2021 | 465.96 Mn |
| Sep 30, 2021 | 437.64 Mn |
| Jun 30, 2021 | 192.30 Mn |